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Human T cell leukemia virus 1 (HTLV-1) gene expression is regulated by both the viral Tax protein and by cellular transcriptional factors.
We have previously shown that immune activation stimuli such as phorbol esters (PMA) and phytohemagglutinin (PHA) cooperate with
HTLV-1 Tax expression to enhance HTLV-1 gene expression in infected T cells through increased activity of the HTLV-1 LTR. We now
extend these studies to demonstrate roles for the T cell receptor complex, Lck, and Ras molecules in the coactivation of the HTLV-1 LTR by
Tax and T cell activation stimuli. We also observe coactivation of Tax-responsive cellular promoter elements containing NF-nB and serum
response factor (SRF) binding sites by Tax and T cell activation stimuli. These results suggest a model whereby T cell receptor stimulation
and Tax expression coactivate HTLV-1 gene expression and cellular gene expression, enhancing activation of latent HTLV-1 and expression
of cellular genes involved in disease pathogenesis.
D 2005 Elsevier Inc. All rights reserved.Keywords: HTLV-1; LTR; Latency; Reactivation; T cell activation; Lck; Ras; SRF; NF-nBIntroduction
HTLV-1 was the first identified human retrovirus
(Poiesz et al., 1980; Yoshida et al., 1982) and was shown
to be the causative agent of adult T cell leukemia/
lymphoma (ATL) (Blattner et al., 1982; Hinuma et al.,
1981) and HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) (Gessain et al., 1985; Osame et
al., 1986). HTLV-1 infection is endemic in a number of
parts of the world, including the southern islands of Japan,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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HTLV-1 infection is also seen in the southern United
States, as well as in immigrants, particularly from the
Caribbean (Manns et al., 1999). Infection with HTLV-1 is
associated with a diverse set of potential clinical outcomes
ranging from asymptomatic infection, to the development
of ATL, HAM/TSP, or a variety of autoimmune syndromes
(reviewed in Ho¨llsberg and Hafler, 1993; Uchiyama,
1997). The molecular basis for the development of each
of these different disorders is unclear, but is likely to be
dependent on complex host–virus interactions, as the
overwhelming majority of HTLV-1-infected individuals
remain asymptomatic, and the likelihood of developing a
particular disease is, in part, determined by the routes and
timing of viral infection. For example, ATL develops in005) 1 – 11
H.-C. Lin et al. / Virology 339 (2005) 1–112less than 3–5% of infected individuals, often those
infected in childhood, with a clinical latency of up to
20–60 years (Mortreux et al., 2003). In contrast, HAM/
TSP may develop in up to 3–5% of individuals infected
later in life, with shorter clinical latency periods.
HTLV-1 infects predominantly human CD4+, CD45RO+
T cells in vivo (reviewed in Ho¨llsberg, 1999). Infection of
CD4+ T cells in vitro results in immortalization and
ultimately growth of IL-2-independent T cells (Popovic et
al., 1983). This in vitro transformation provides an interest-
ing analogy to the proliferation of oligoclonal and ultimately
monoclonal populations of T cells seen in association with
HTLV-1-induced diseases. The detailed mechanisms
responsible for this immortalization are not yet known;
however, they clearly involve the activities of the HTLV-1
transcriptional transactivator, Tax (reviewed in Franchini et
al., 2003; Yoshida, 2001). In addition to potently activating
transcription of the HTLV-1 long terminal repeat (LTR)
through the LTR Tax response elements (TREs), Tax
activates transcription of a large array of cellular genes,
including genes likely to be directly involved in T cell
transformation (reviewed in Azran et al., 2004). Tax also
affects the functions of cell cycle regulatory genes (Jeang,
2001). The ability of HTLV-1 to induce proliferation of
infected cells undoubtedly plays a role in pathogenesis of
the HTLV-1-associated disorders. Nevertheless, there are
clearly fundamental differences between the rapid trans-
formation of T cells in vitro by HTLV-1 and the long-term in
vivo development of ATL, including differences in HTLV-1
gene expression in the two different settings.
Viral latency and reactivation is a common feature of
retroviral infections and may contribute to viral persistence
and disease pathogenesis. In human immunodeficiency
virus type 1 (HIV-1) infection, viral latency has been well
characterized both molecularly and in the effects that
latently infected cells have on viral persistence and anti-
viral therapy (Persaud et al., 2003). Latency in HTLV-1
infection has been less characterized, although evidence for
in vivo latency and identification of in vitro cellular models
of latent infection have both been described. In vivo, it is
clear that HTLV-1 infection can result in either silent or
productive infection of individual T cells. For example, in
HAM/TSP patients, up to 15–18% of T cells in peripheral
blood were HTLV-1 infected, although only a few cells
(perhaps 1/5000) expressed high levels of HTLV-1 Tax in
vivo (Ho¨llsberg, 1999). In contrast, HTLV-1 Tax expression
was rapidly induced following culture of PBMCs from
infected patients in the presence of PHA and IL-2,
suggesting that many cells in vivo may be latently infected
and contain inducible proviruses (Kinoshita et al., 1989).
Not all latently infected cells contain inducible HTLV-1
genomes (Richardson et al., 1997) and many contain
proviruses that have sustained various inactivating muta-
tions (Rose et al., 2000); however, latently infected cell
clones have been described that clearly exhibited inducible
HTLV-1 gene expression in culture (Richardson et al.,1997). In addition to proviral mutational inactivation,
transcriptional repression of HTLV-1 LTR function has
been proposed to contribute to viral latency. This may be
due to either cis-acting epigenetic events such as methyl-
ation of HTLV-1 proviral DNA (Saggioro et al., 1991;
Takeda et al., 2004) and recruitment of histone deacetylases
to the LTR promoter (Ego et al., 2002; Lemasson et al.,
2004; Lu et al., 2004), or effects of cellular transcription
factors such as NF-nB-2 p100-mediated inhibition of Tax
(Beraud et al., 1994), ICER-mediated inhibition of Tax
activation through CREB/ATF (Newbound et al., 2000), and
the possible inhibitory effects of CREB/ATF complexes
binding to the LTR R region (Xu et al., 1994).
Several groups have begun to examine the types of
stimuli that may reactivate expression of latent HTLV-1.
Studies from our laboratory (Lin et al., 1998) have identified
HTLV-1-infected T cell lines that express only very low
levels of HTLV-1 RNA and proteins, but which can be
induced to express much higher levels of HTLV-1 gene
products by treatment with T cell activation stimuli, such as
phytohemagglutinin (PHA) and phorbol esters (PMA).
Although the proviruses in these cells are not completely
silent, the ability to markedly activate very limited basal
HTLV-1 gene and protein expression suggests that these
cells may be a model of HTLV-1 latency and reactivation.
These studies suggested that these activation stimuli
cooperate with HTLV-1 Tax to synergistically activate
HTLV gene expression and HTLV-1 LTR-mediated tran-
scription. Similarly, Dumais et al. have demonstrated that
the combination of T cell receptor and CD28 stimulation
with prostaglandin E2 treatment results in strong activation
of the HTLV-1 LTR and integrated HTLV-1 provirus
(Dumais et al., 2003). These authors have further implicated
a role for tyrosine phosphorylation in this activation
(Langlois et al., 2004). Lairmore et al. demonstrated that
anti-CD2 antibody activated HTLV-1 transcription from
infected cells (Guyot et al., 1997), and have also demon-
strated that cellular stresses, such as those induced by heat
stress and sodium arsenite enhanced HTLV-1 gene expres-
sion in chronically infected cell lines (Andrews et al., 1995).
This activity may be independent of Tax and was mediated
through effects on formation of RNA polymerase complexes
at the promoter (Andrews et al., 1997). Cellular stresses
such as UV light (Okada and Jeang, 2002) and other DNA
damaging agents (Torgeman et al., 2001a) have also been
shown to activate integrated LTRs. Others have also shown
activation of the HTLV-1 LTR by phorbol esters in non-T
cells (Jeang et al., 1988; Torgeman et al., 2001b), and
cooperative effects of Tax and signal transduction pathways
involving Ras have also been demonstrated (Pozzatti et al.,
1990). Overall, these studies strongly suggest that immune
activation, cellular stresses, and intracellular signal trans-
duction pathways may activate the transcription of inte-
grated HTLV-1 proviruses and therefore may activate
expression of latent HTLV-1. In this study, we demonstrate
that T cell activation signals mediated through Lck and Ras
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and that cellular promoters responsive to Tax may exhibit
similar coactivation by T cell activation stimuli. These
observations begin to define pathways and targets that may
mediate activation of latent HTLV-1 in vivo and suggest
roles that T cell activation may play in the pathogenesis of
HTLV-1-induced disease.Results
Activation of HTLV-1 gene expression through T cell
receptor stimulation
Previously, we demonstrated that treatment of T cells
chronically infected with HTLV-1 with PHA or PMA
resulted in induction of expression of HTLV-1 RNA and
proteins and enhanced Tax transactivation of the HTLV-1
LTR in stimulated cells (Lin et al., 1998). These resultsFig. 1. Activation of HTLV-1 gene expression through T cell receptor stimulatio
receptor activation. (Upper panel) Whole-cell extracts were prepared from FS cells,
with OKT3 antibody. Western blot analysis was performed using antisera directed
(Lower panel) FS cells were incubated with anti-CD2/CD3/CD28-loaded anti-Bio
cell lysates using anti-sera directed against the HTLV-1 Tax protein. Anti-actin antib
directed gene expression in FS cells. The pHTLV-1Luc plasmid was transfected int
transfection. Luciferase activity was assayed 40 h after transfection. Average
transfections are shown and the fold activation compared to untreated cells is indi
Luc plasmid was cotransfected into Jurkat cells (left panel) or J.RT3 cells (right pan
with or without treatment with PHA or PMA. Reporter assays were performed as d
bars) from triplicate transfections are shown and the fold activation compared tosuggested that immune activation stimuli, working through
the T cell receptor signaling pathway, may activate
integrated HTLV-1 proviruses. FS cells, an HTLV-1-infected
T cell line derived from a HAM/TSP patient (Dezzutti et al.,
1993), normally express low or non-detectable levels of the
HTLV-1 Tax protein. We used two different approaches to
directly examine the effect of T cell receptor signaling on
HTLV-1 gene expression in FS cells. In the first approach
(Fig. 1A, upper panel), FS cells were incubated with anti-
CD3 antibody to induce T cell receptor crosslinking. This
experiment used a well-established system for inducing
antibody crosslinking of target cell surface receptors, in
which the antibody under study is bound to the surface of
irradiated murine l-thymidine kinase-negative cells which
express the human Fc gamma RII receptor (CDw32 L cells)
(Peltz et al., 1988). The CDw32 L cells were incubated first
with OKT3 antibody (anti-CD3 antisera) to coat their
surface with the anti-CD3 antibody and then cocultivated
with FS cells to allow binding of the OKT3 antibody to CD3n. (A) Activation of Tax protein expression in FS cells subjected to T cell
which were co-cultivated for 48 h with mouse CDw32 L cells pre-incubated
against the HTLV-1 Tax protein. Anti-actin antibody was used as control.
tin MACSiBead particles for 48 h. Western blot analysis was performed on
ody was used as control. (B) T cell activation signals activate HTLV-1 LTR-
o FS cells. PHA, PMA or anti-CD2/CD3/Cd28 beads were added 24 h after
luciferase activities with standard deviations (error bars) from triplicate
cated. (C) Role of T cell receptor in HTLV-1 LTR activation. The pHTLV1
el), a CD3-negative Jurkat cell line, along with the Tax expression plasmid,
escribed above. Average luciferase activities with standard deviations (error
the luciferase value from untreated cells in the absence of Tax is indicated.
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anti-CD3 antibody induced expression of the HTLV-1 Tax
protein in FS cells approximately 4-fold as compared with
the very low basal level in untreated cells. In the second
approach, we incubated FS cells with beads pre-coated with
anti-CD2, anti-CD3, and anti-CD28 antibodies to induce T
cell receptor crosslinking and T cell activation. Untreated
and treated FS cells were lysed and examined for HTLV-1
Tax gene expression by Western blot analysis. As shown in
Fig. 1A lower panel, treatment of FS cells with the anti-
CD2/CD3/CD28 coated beads led to a marked induction of
HTLV-1 Tax protein expression from essentially undetect-
able levels to easily detectable Tax protein. Levels of control
actin protein actually slightly decreased following treatment.
These results confirm that, as previously suggested by PHA
treatment, direct T cell receptor stimulation is capable of
inducing Tax expression in these latently infected cells.
Our previous studies suggested that the PHA and PMA
induction of HTLV-1 protein expression was due to
enhanced transcription of the HTLV-1 LTR. PHA treatment
resulted in increased HTLV-1 RNA expression in FS cells,
and in increased Tax-mediated transactivation of the HTLV-
1 LTR in transiently transfected Jurkat T cells (Lin et al.,
1998 and Fig. 1C, left). In order to confirm that LTR
activation of transfected LTR-reporter plasmids transiently
transfected into Jurkat cells models the LTR activation seen
in the FS cells, we transfected the HTLV-1 LTR-luciferase
plasmid directly into FS cells and subjected the transfected
cells to treatment with PHA, PMA, or incubation with the
anti-CD2/CD3/CD28 antibody-coated beads. As shown in
Fig. 1B, PHA, PMA, and antibody crosslinking of T cell
surface markers all resulted in significant activation of the
transfected HTLV-1 LTR in the FS cells, leading to a 2.3-,
4.2-, and 3.5-fold activation of reporter gene expression,
respectively. Thus, cotransfection of T cells with the HTLV-
1 LTR-luciferase reporter plasmid and a Tax-expressing
plasmid, followed by treatment of transfected cells with T
cell activation stimuli, appears to mimic the activation of the
endogenous HTLV-1 LTRs and endogenous Tax expression
present in FS cells.
In order to further understand the mechanisms respon-
sible for HTLV-1 LTR activation by T cell activation stimuli,
we have employed transient transfection of Jurkat T cell
lines in which components of the T cell activation pathway
are mutated. To further assess the role of CD3 on PHA/Tax-
mediated coactivation of the HTLV-1 LTR, we transfected a
CD3-negative mutant of Jurkat T cells (J.RT3 cells; Ohashi
et al., 1985) with the HTLV-1 LTR reporter plasmid, with or
without the LTR-Tax expression plasmid (Fig. 1C). Trans-
fected cells were either untreated or treated with PHA or
PMA. As a control, the results of transfection of wild-type
Jurkat cells are shown in the left panel for comparison and
demonstrate coactivation of the HTLV-1 LTR by Tax
transfection and PHA or PMA treatment (35- and 30-fold,
respectively), but only low levels of direct activation of the
LTR by these stimuli (1.1- and 1.5-fold) similar to ourprevious observations (Lin et al., 1998). As shown in Fig.
1C right panel, in J.RT3 cells, PHA no longer enhanced
Tax-mediated HTLV-1 promoter activity, while PMA still
cooperated with Tax to activate HTLV-1 LTR-directed gene
expression. These data suggest that the CD3/TCR complex
is required for coactivation of HTLV-1 expression in
response to PHA stimulation; however, it is not required
for activation by phorbol esters, which act on protein kinase
C isoforms downstream of TCR crosslinking in the process
of T cell activation.
Role of intracellular signaling molecules in TCR-mediated
coactivation of the HTLV-1 LTR
In our previous study, we tested the effects of inhibitors of
steps in the T cell activation signal transduction pathway on
the activation of HTLV-1 gene expression and of the HTLV-1
LTR by Tax/PHA or Tax/PMA. In those studies, a tyrosine
kinase inhibitor potently blocked both PHA- and PMA-
induced activation, while a PKC inhibitor blocked activation
by PMA but not PHA. Lck is an important tyrosine kinase in
T cell receptor-mediated activation, which plays a role
following TCR crosslinking in assembling the signaling
machinery at the membrane, and activating a series of
downstream kinases (reviewed in Chan et al., 1994; Singer
and Koretzky, 2002). JCaM.1 cells are mutant Jurkat T cells,
defective in Lck tyrosine kinase function (Gupta et al., 1994).
We employed JCaM.1 cells to test whether Lck played a role
in the activation of the HTLV-1 LTR following PHA
treatment. JCaM.1 cells were transiently transfected with
the HTLV-1 LTR luciferase plasmid, with or without an
HTLV-1 LTR-Tax expression plasmid. Transfected cells were
treated with PHA or PHA. While Tax transfection and PMA
treatment still resulted in marked synergistic activation of the
HTLV-1 LTR in JCaM.1 cells, PHA plus Tax only minimally
further activated HTLV-1 LTR expression beyond that
observed with Tax alone (Fig. 2). Transfection of an Lck
expression plasmid back into JCaM.1 cells restored signifi-
cant levels of coactivation by Tax and PHA, although these
levels remained lower than those observed in wild-type cells
(Fig. 2). Overexpression of Lck, even in the absence of PHA,
also modestly enhanced Tax activation of the LTR. These
data suggest that Lck plays a significant role in transduction
of the PHA/TCR signal for activation of HTLV-1 expression,
and itself may enhance Tax transactivation.
Ras proteins play an important role in signal transduction
mediated by the T cell receptor following antigenic
stimulation (reviewed in Cantrell, 2003). As an initial test
of the possible role of Ras proteins in signal transduction
pathways leading to synergistic activation of the HTLV-1
LTR by T cell activation stimuli and Tax, we assayed the
effects of activated Ras on HTLV-1 LTR expression. Jurkat
cells were cotransfected with an expression plasmid encod-
ing the oncogenically activated form of v-H-Ras. As shown
in Fig. 3A, while Ras alone has little effect on HTLV-1 LTR
function in these cells, Ras plus Tax cotransfection results in
Fig. 3. Role of Ras in activation of the HTLV-1 LTR by PHA/Tax or PMA/
Tax. (A) The pHTLV-1 Luc plasmid was cotransfected into Jurkat cells with
the Tax expression plasmid and with an activated v-Ras expression vector
(pCMV-vRas). Stimuli were added 24 h after transfection. Luciferase
activity was assayed 40 h after transfection. (B) Effect of dominant-negative
H-Ras on PHA/Tax or PMA/Tax coactivation. The pHTLV-1 Luc plasmid
was cotransfected into Jurkat cells with the Tax expression plasmid
(pHTLV-1 LTR-Tax) and a dominant-negative H-Ras expression vector
(pMZH17N). Stimuli were added 24 h after transfection. Luciferase activity
was assayed 40 h after transfection. Average luciferase activities with
standard deviations (error bars) from triplicate transfections are shown and
the fold activation compared to untreated cells is indicated.
Fig. 2. Role of Lck in activation of the HTLV-1 LTR by PHA/Tax or PMA/
Tax in T cells. The pHTLV-1 Luc plasmid was cotransfected into JCaM.1,
an Lck-defective Jurkat cell line, along with the Tax expression plasmid,
with or without cotransfection of an Lck expression plasmid (pcDNA-Lck).
Stimuli were added 24 h after transfection. Luciferase activity was assayed
40 h after transfection. Average luciferase activities with standard
deviations (error bars) from triplicate transfections are shown and the fold
activation compared to untreated cells is indicated.
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alent to that seen with Tax plus PHA or PMA. This is
particularly interesting in view of the reported co-trans-
forming activities of Ras and Tax (Pozzatti et al., 1990). In
the presence of transfected Ras, PHA or PMA treatment had
little additional effect on Tax transactivation of the HTLV-1
LTR. These data suggest that Ras can potently cooperate
with Tax in activation of Tax-responsive genes. The fact that
Ras cooperation with Tax results in a coactivation similar to
that observed with PHA or PMA and does not further
enhance the PHA/Tax or PMA/Tax activation is consistent
with Ras being in the same signal transduction pathway as
PHA or PMA treatment in inducing LTR activation, as
might be expected based on its known roles in TCR-
mediated signal transduction. As shown in Fig. 3B,
conversely, cotransfection of a dominant-negative H-Ras
(Feig and Cooper, 1988) resulted in a significant reduction
of Tax/PHA or Tax/PMA coactivation. Interestingly, the
dominant-negative Ras also reduced Tax-mediated trans-
activation approximately 2-fold. It is therefore difficult to
specifically identify an effect of Ras in the PHA or PMA
coactivation pathway that is distinguishable for the effects
of Ras on Tax itself but this result raises the interesting
possibility that Tax-mediated transactivation itself is
enhanced by Ras-regulated pathways.
Effects of T cell activation stimuli on Tax activation of
cellular promoter elements
In addition to regulating HTLV-1 gene expression, Tax
has also been shown to alter cellular gene expression
through a number of different transcriptional regulatory
pathways (reviewed in Azran et al., 2004). These include
activation of cellular promoters containing NF-nB binding
sites, serum response elements, CREB/ATF family protein
binding sites, and other transcription factors. These effectson cellular promoters are likely to play important roles in
Tax-mediated transformation of T cells. We were interested
in assessing whether Tax could also cooperate with PHA or
PMA in the activation of promoters containing these
transcription factor binding sites. Tax activation of pro-
moters containing NF-nB sites likely plays a critical role in
T cell transformation. We therefore tested whether a
promoter directed by multimerized NF-nB binding sites
derived from the IL-6 gene, a known Tax-responsive
promoter (Muraoka et al., 1993), would exhibit increased
activation by cotransfection with Tax and treatment with
PHA or PMA. As shown in Fig. 4A, PHA or PMA
stimulation alone activated the IL-6 nB promoter 7- to 8-
fold, in the absence of Tax. HTLV-1 Tax activated the
promoter approximately 8-fold. The combination of PHA or
PMAwith Tax cotransfection activated the IL6-nB promoter
approximately 7- to 9-fold over that seen with Tax alone, or
65- to 80-fold over basal promoter activity. Thus, for the
NF-nB-directed promoter, PMA and PHA exerted a similar
effect on promoter activity in the presence or absence of
Fig. 4. Effects of T cell activation stimuli on Tax-mediated-activation of
cellular promoter elements. (A) Activation of an NF-nB-responsive
promoter by Tax/PHA and Tax/PMA. The pIL6nB-Luc reporter plasmid
was transfected into Jurkat T cells, with or without cotransfection of the Tax
expression plasmid. PHA and PMA were added at 24 h after transfection.
Luciferase activity was assayed 40 h after transfection. (B) Activation of
serum-responsive element containing promoter by Tax/PHA and Tax/PMA.
The pSRE-Luc reporter plasmid was transfected into Jurkat T cells, with or
without cotransfection of the Tax expressing plasmid. PHA and PMAwere
added at 24 h after transfection. Luciferase activity was assayed 40 h after
transfection. (C) Activation of the HSV-TK promoter by Tax/PHA and Tax/
PMA. A plasmid containing the Renilla luciferase reporter gene under the
control of the HSV-TK promoter (pRL-TK) was transfected into Jurkat T
cells, with or without cotransfection of the Tax-expressing plasmid. PHA
and PMA were added at 24 h after transfection. Renilla Luciferase activity
was assayed 40 h after transfection. Average luciferase activities with
standard deviations (error bars) from triplicate transfections are shown and
the fold activation compared to untreated cells is indicated.
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PMA/PHA resulted in a marked increase in overall promoter
activity, but not associated with the kind of synergistic
promoter activation seen for the HTLV-1 LTR. The serum
response elements (SREs) direct transcription of immediate
early genes, such as c-fos, also likely to play important roles
in Tax-mediated transformation. To assess whether PHA or
PMA would cooperate with Tax in the activation of SRE-
containing promoters, a reporter plasmid directed by multi-
ple copies of SREs was transfected in Jurkat T cell, with
HTLV-1 Tax cotransfection (Fig. 4B). Again, PHA and
PMA treatment, as well as Tax cotransfection, each
substantially increased the very low basal levels of SRE
promoter activity, while the combination of Tax and PHA or
PMA again resulted in markedly higher levels of SRE
promoter activity. Tax cotransfection or PHA/PMA treat-
ment did not activate the herpes simplex virus thymidine
kinase (TK) promoter (Fig. 4C), suggesting the observed
PHA/Tax or PMA/Tax coactivation is promoter-specific,
dependent on basal Tax activation of target promoters, and
is therefore not a general property of these stimuli.Discussion
Our previous study (Lin et al., 1998) showed that the T
cell activation stimuli, PHA and PMA, induced HTLV-1
gene expression from chronically infected T cell lines. This
induction appeared to be mediated through synergistic
activation of the HTLV-1 LTR by these agents in combi-
nation with the HTLV-1 Tax transactivator. In this study, we
have further characterized the signal transduction pathways
responsible for the induction of HTLV-1 transcription
mediated by T cell activation stimuli and Tax. We have
also demonstrated strong enhancement of cellular promoter
elements through the combined effects of Tax and T cell
activation stimuli. An important component of PHA-
induced T cell activation is contributed through binding
to, and crosslinking of, components of the CD3/T cell
receptor complex. In our previous study, only the two cell
lines expressing surface CD3 exhibited activation of HTLV-
1 gene expression in response to PHA, suggesting that
crosslinking of the CD3/TCR complex might be the first
step in PHA-induced HTLV-1 activation. We extended this
observation by demonstrating that activation of T cells by
crosslinking CD3/TCR on the surface of HTLV-1-infected
FS cells also resulted in enhanced Tax expression. Similarly,
crosslinking of a combination of CD2, CD3, and CD28 also
induced HTLV-1 gene expression in the FS cells. Further-
more, PHA no longer cooperated with HTLV-1 Tax in
activation of the HTLV-1 in J.RT3 cells, a CD3-negative
Jurkat T cell line, also consistent with the role for CD3 in
the coactivation by PHA and Tax. Interestingly, a recent
study has demonstrated potent activation of HTLV-1 LTR
expression by a combination of crosslinking of CD3 and
CD28, coupled with treatment with prostaglandin E2
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both HTLV-1 LTR-luciferase plasmids, as well as of HTLV-
1 p19 production from chronically infected cells induced by
CD3 alone, was also observed in that study, consistent with
the results that we have seen. Induction of HTLV-1 gene
expression by CD3/TCR crosslinking is consistent with the
hypothesis that immune activation may activate expression
of latent HTLV-1, thus contributing to HTLV-1 patho-
genesis. Our observations are complementary to those
demonstrating additional important interactions between T
cell activation and HTLV-1. The HTLV-1 p12(I) protein
induces NFAT activation through cytoplasmic calcium
release mimicking T cell activation (Ding et al., 2002).
Interestingly, in these studies, p12(I) expression cooperated
with PMA treatment in activation of NFAT (Ding et al.,
2002), suggesting that at least two HTLV-1 proteins (Tax
and p12(I)) have the ability to cooperate with T cell
activation stimuli to further alter gene expression in infected
cells. The HTLV-1 p30II protein has recently been shown to
selectively activate genes involved in T cell activation and
thus may also contribute to viral gene expression and
pathogenesis through effects on T cell activation and
proliferation, as well as effects on viral gene expression
(Michael et al., 2004). The p30II protein may also have an
important role in the establishment of latency. Nicot et al.
have shown that p30II expression retains the mRNA’s
encoding Tax and Rex in the nucleus of infected cells, thus
inhibiting viral gene expression (Nicot et al., 2004). Thus,
the p30II protein, as well as Tax and Rex, through their
interactions with cellular proteins may be critical determi-
nants of viral latency or gene expression. It will be of
interest to examine the function of p30II in unstimulated and
stimulated FS cells.
T cell receptor activation involves the activation of TCR-
associated tyrosine kinases, followed by induction of several
signaling pathways, including those involving Ras and
Rho family GTPases, inositol phospholipids, protein
kinase C, and calcium activation. Employing an Lck-
defective mutant of Jurkat T cells allowed us to demonstrate
that the Lck tyrosine kinase plays an important role in
transduction of the PHA signal for activation of HTLV-1
expression, but is not required for PMA-induced LTR
activation. Reintroduction of Lck by cotransfection with the
LTR and Tax restored PHA-induced coactivation of the
HTLV-1 LTR in these cells. This experiment complements
and extends that of Dumais et al. (2003) who showed a
similar dependence of CD3/CD28 and prostaglandin E2
activation of the LTR on Lck function and is consistent with
more recent studies showing a strong activation of the
HTLV-1 LTR by tyrosine phosphatase inhibition (Langlois
et al., 2004). Oncogenically activated Ras also strongly
cooperated with Tax in activation of the HTLV-1 LTR. PHA
or PMA treatment had little further effect over that induced
by Ras and Tax. Cotransfection of a dominant-negative H-
ras resulted in a reduction of Tax activation itself, as well as
in PHA or PMA plus Tax coactivation. These data suggestthat activated Ras can potently cooperate with Tax and may
contribute both to basal Tax activation as well as to the
PHA/Tax or PMA/Tax signal transduction pathway. The
presence of significant residual coactivation by the PHA and
PMA, even in the presence of dominant-negative form of
Ras, suggests that additional signal transduction pathways
generated in response to PHA or PMA are also important in
PHA/Tax or PMA/Tax coactivation. Furthermore, the
marked coactivation of the HTLV-1 LTR by activated Ras
and HTLV-1 Tax, independent of PHA or PMA treatment,
suggests that other signaling pathways that use Ras may also
activate HTLV-1 gene expression in vivo. Interestingly, H-
Ras and Tax have been previously shown to cooperate in the
oncogenic transformation of primary rodent fibroblasts
(Pozzatti et al., 1990). This suggests that cooperation
between these two oncogenes may play a role in the
induction of ATL. Similarly, activated Lck has been shown
to cooperate with Tax in inducing growth factor-independ-
ent growth of hematopoietic cells (Miyazaki et al., 1996).
The mechanisms by which T cell activation stimuli
cooperate with Tax to activate HTLV-1 LTR transcription
remain unclear. To date, we have been unable to dissociate
the coactivation effects from the effects of Tax alone on
LTR expression (Lin et al., in preparation), suggesting
either that transcriptional regulators induced by PHA or
PMA are also dependent on Tax in order to activate LTR
expression or that Tax itself is a target of the T cell
activation stimuli. It is interesting to note that PMA has
been suggested to increase Tax phosphorylation (Fontes et
al., 1993), providing one possible mechanism for the
coactivation induced by Tax and this stimulus. It is
important to note that the transfection assays that we have
employed express both Tax and reporter gene expression
under the control of the HTLV-1 LTR, mimicking the
provirus in which Tax and other HTLV-1 genes are
controlled by the LTR. Thus, an additional explanation
could be the generation of a very strong positive feedback
loop in which the low levels of LTR activation seen with
PHA or PMA alone (1.1- to 1.5-fold activation) result in
sufficient increases in Tax expression to generate a strong
amplification of LTR-directed expression of both Tax and
the reporter gene. In this scenario, it would also be difficult
to definitely dissociate the effects of PHA or PMA on the
LTR from those due to increasing Tax synthesis.
HTLV-1 Tax also activates cellular promoters in addition
to the HTLV-1 LTR (reviewed in Azran et al., 2004),
through effects on subsets of CREB/ATF-, SRE-, and NF-
nB-dependent promoters. Our data demonstrated that PHA
or PMA signals further enhanced HTLV-1 Tax activation of
promoters containing SRE- or NF-nB binding sites. Tax
activates c-fos transcription by interacting directly with the
serum response factor, which binds the central CArG
sequence of the serum response element (Fujii et al.,
1992). Tax activation of the SRE requires binding of the
ternary complex factors (TCF) to the Ets box adjacent to the
CArG box and Tax also directly interacts with TCFs in vitro
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been shown to have a functional serum response element at
120 (Wycuff et al., 2004), suggesting that this site may
also participate in LTR coactivation. These data suggest that
PHA/Tax or PMA/Tax may activate the HTLV-1 LTR and
SRE containing promoters through similar mechanisms. The
mechanisms of Tax-mediated NF-nB activation are complex
(Jeang, 2001). Recent data suggest Tax mainly affects NF-
nB signaling in the cytoplasm through association with, and
activation of, the InB kinase complex (Li and Gaynor, 2000;
Sun et al., 2000). Tax has also been shown to bind to the
NF-nB p50 and p52 subunits in the nucleus, potentially
directly enhancing NF-nB DNA binding and target gene
transcription in the nucleus. We do not yet know the level
through which PMA or PHA combine with Tax to increase
NF-nB-mediated transcription. PHA and PMA seem to
exhibit the same relative effects in the presence or absence
of Tax, suggesting that they may exert separate additive
effects on NF-nB-dependent transcription. It is important to
note that cooperative promoter activation is not a feature of
all cellular promoters or even all NF-nB-regulated pro-
moters. Tax and T cell activation stimuli do not cooperate to
activate the thymidine kinase promoter nor do they
coactivate the promoter of the Bfl-1 gene (data not shown),
an NF-nB target gene regulated through a complex
enhanceosome mechanism (Edelstein et al., 2003).
The pathogenesis of HTLV-1-associated diseases is
clearly complex. Only a small fraction of infected indivi-
duals will develop disease after variable clinical latency
periods. It is likely that host and viral factors both play
important roles in the process. Latently infected cells are
present in the blood of infected patients (Ho¨llsberg, 1999;
Kinoshita et al., 1989), potentially mediated through tran-
scriptional repression by methylation of proviral DNA
(Saggioro et al., 1991; Takeda et al., 2004). The potent
cytotoxic T cell (CTL) response against Tax epitopes
indicates that some level of Tax expression is persistent in
vivo, however, and Tax-expressing cells may be readily
cleared from the blood [reviewed in (Bangham, 2003)]. On
the other hand, the high levels of CTL against Tax
expressing cells may also serve as a strong selective
pressure against Tax expression, thereby potentially favor-
ing maintenance of latent infection. Other laboratories have
demonstrated that anti-CD2 antibodies (Guyot et al., 1997)
and cellular stresses activate HTLV-1 transcription from
infected cells (Andrews et al., 1995), and our studies, as
well as those of Dumais et al. (2003), suggest that T cell
activation could also serve to increase HTLV-1 gene
expression in vivo. This could result in increased levels of
Tax in infected T cells, enhancing proliferation of the
infected cells, through the effects of Tax-induced cellular
proteins. Tax expression, which may induce either pro- or
anti-apoptotic activities (Ho¨llsberg, 1999), could also serve
to overcome T cell apoptosis due to activation-induced cell
death (AICD). Thus, we hypothesize that activation of Tax
expression through T cell receptor stimulation would lead toincreased T cell proliferation and inhibition of AICD,
contributing to the oligoclonal T cell expansions seen in
both pre-ATL as well as in HAM/TSP. This is similar to the
model proposed by Azrin et al., in which cellular stresses
activate HTLV-1 Tax expression and induce DNA damage
and mutations, while induced Tax in turn blocks induction
of cell death by these stimuli (Azran et al., 2004; Torgeman
et al., 2001a). Furthermore, in the setting of T cell
activation, the nature of the specific antigen-TCR inter-
actions may lead to proliferation of subsets of T cells that
may contribute to pathogenesis. It is also possible that such
stimulation could increase HTLV-1 virus production, lead-
ing to spread of HTLV-1 within the infected individual to
previously uninfected T cells. Some on-going replication
occurs in vivo, as evidenced by the ability of reverse
transcriptase inhibitors to decrease proviral load (Taylor et
al., 1999). Most studies, however, demonstrate that
increased proviral load is the result of expansion of already
infected cells (Cavrois et al., 1998; Mortreux et al., 2003).
Interestingly, chronic infection with Strongyloides stercor-
alis (Ss) results in a significantly higher HTLV-1 provirus
load and an oligoclonal expansion of CD4+25+ T cells in
dually infected, HTLV-1-positive individuals, associated
with shortened clinical latency for the development of
ATL (Gabet et al., 2000). Furthermore, Ss antigens may
enhance T cell proliferation through activation of the IL-2/
IL-2 receptor (Satoh et al., 2002). These observations
parallel our hypothesis that T cell activation may enhance
expression of latent HTLV-1 and contribute to the develop-
ment of HTLV-1-associated disease phenotypes. Clearly
further studies of the association of T cell activation and
HTLV-1 activation in vivo will be required to further
validate this hypothesis and to provide greater under-
standing of the relationship between HTLV-1 latency, viral
activation, and disease pathogenesis.Materials and methods
Cell lines
CDw32 L (Human Fc gamma RII receptor expressing
mouse L TK-cells) (Peltz et al., 1988), obtained from the
American Type Culture Collection, Rockville, MD, USA,
on the behalf of DNAX Research Institute (Palo Alto,
CA), were maintained in DMEM media (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS; Gemini Bio-Product, Woodland, CA). Jurkat T cells,
as well as the derived mutants, CD3-defective J.RT3 cells
(ATCC, TIB-153) (Ohashi et al., 1985), and Lck-mutated
JCaM.1 cell (ATCC, CRL-2603) (Straus and Weiss, 1992),
were maintained in RPMI 1640 media (Invitrogen,
Carlsbad, CA) supplemented with 10% FBS. FS cells
(Dezzutti et al., 1993), an HTLV-1-infected T cell line
derived from a HAM/TSP patient, were maintained in
RPMI 1640 medium containing 15% FBS and 50 U/ml
H.-C. Lin et al. / Virology 339 (2005) 1–11 9recombinant human interleukin-2 (IL2; Roche Applied
Science, Indianapolis, IN).
Plasmids
pHTLV-1 Luc plasmid, an HTLV-1 LTR-luciferase
reporter plasmid, has been described previously (Lin et
al., 1998). pHTLV-1 Tax (Nerenberg et al., 1987), a Tax
expression vector directed by the HTLV-1 LTR, was
provided by Dr. Susan Marriott (Baylor University,
Houston, TX). pcDNA-Lck, a plasmid expressing Lck
protein under the control of the CMV promoter, was
provided by Dr. S. Bour (NIAID, NIH, Bethesda, MD).
pCMV-vRas, a plasmid expressing v-H-Ras under the
control of the CMV promoter, was provided by Dr. C.
Ge´linas (UMDNJ-RWJMS, Piscataway, NJ). Other plas-
mids used included pMZH17N, expressing a human
dominant-negative form of H-Ras (Asn17; Feig and
Cooper, 1988) under the control of the CMV promoter
(constructed by Dr. M. Malumbres and a kind gift of Dr.
A. Pellicer, NYU Medical Center, New York, NY); pIL6-
nB; a reporter plasmid containing three copies of the IL6-
nB motif directing expression of the luciferase gene (Suh
et al., 2002); pSRE-Luc, a reporter plasmid containing five
repeats of the serum-responsive element (SRE) directing
expression of luciferase (Stratagene, La Jolla, CA); and
pRL-TK, a herpes simplex virus thymidine kinase (HSV-
TK) promoter directing expression of the Renilla luciferase
reporter gene (Promega, Madison, WI).
T cell activation and Western blot analysis
In the first approach for T cell activation, FS cells were
cocultivated with irradiated (70 Gray) CDw32 L cells as
described (Planken et al., 1996), which were pre-incubated
with OKT3 antisera (murine OKT3, 5 Ag/ml; Ortho
Diagnostic System, Raritan, NJ) for 48 h. In the second
approach for T cell activation, FS cells were incubated with
MACSiBead particles coated with antibodies against human
CD2, CD3, and CD28 (T Cell Activation Kit, Miltenyi
Biotec., Auburn, CA) according manufacturer’s instruc-
tions. 2.5  106 of FS cells were incubated with anti-Biotin
MACSiBead particles (loaded with equal amounts of
biotinylated antibodies against CD2, CD3, and CD28), at
the ratio of 2:1 for 48 h. Total protein lysates were prepared
by lysis of 106 cells in 250 Al of radioimmunoprecipitation
assay (RIPA) solution (10 mM Tris [pH 8.0], 10 mM EDTA
[pH 8.0], 100 mM NaCl, 1% Nonidet P-40, 0.25 mg of
aprotonin per ml, 2 mM phenylmethylsulfonyl fluoride, 1
mM dithiothreitol, 0.5% sodium dodecyl sulfate [SDS]).
Protein concentrations were determined by the BCA Protein
Assay Reagent (Pierce Biotechnology, Rockford, IL).
Twenty-five micrograms of total protein was electrophor-
esed through SDS–12.5% polyacrylamide gels and trans-
ferred to nitrocellulose filters (Protran BA85, Schleicher and
Schuell BioScience, Keene, NH) with an electrotransferapparatus. The filter was blocked by pre-incubation with 5%
skim milk in phosphate-buffered saline–Tween 20 and
incubated with Tax antibody (1:100 dilution, HTLV-1 Tax
hybridoma 168A51-2, AIDS Research and Reference
Program, Bethesda, MD). Control actin antibody (Catalog
# A2066, Sigma-Aldrich, St. Louis, MO) was used at a
1:500 dilution. Antibody binding was detected with the ECL
detection kit (Amersham Biosciences, Piscataway, NJ).Transfection and luciferase assay
Reporter plasmids (5 Ag), with or without pHTLV-1 Tax
(1 Ag), were introduced into T cells (107 cells per
transfection) by DEAE-dextran transfection (Dorsett et al.,
1983). Sixteen hours after transfection, cells were treated
with Phytohemagglutinin (PHA-P, L9132, 5 Ag/ml, Sigma-
Aldrich, St. Louis, MO), phorbol 12-myristate 13-acetate
(PMA, P1585, 50 ng/ml, Sigma-Aldrich, St. Louis, MO), or
incubated with MACSiBead particles coated with antibodies
against human CD2, CD3, and CD28 (T Cell Activation
Kit, Miltenyi Biotec., Auburn, CA) according manufactur-
er’s instructions. Cells were lysed and assayed for luciferase
activity at 40 h after transfection as described by Luciferase
Assay system (Promega, E4531, Madison, WI). Protein
concentrations were detected by the BCA Protein Assay Kit
(Pierce Biotechnology, Rockford, IL). Luciferase activity
was normalized to protein concentration (presented as
activity per 20 Ag cellular protein). Average luciferase
activities were determined for triplicate transfections and
standard deviations indicated by the error bars.Acknowledgments
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